Phase 3 N=28 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
Acromegaly
Primary: Change in Growth Hormone (GH) Level From Screening to End of Study (Week 24) — -1.7; -2.1 µg/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=497 Naproxen Sodium Extended-Release Actual Use Study
Pain
Primary: Use Days With One or More Misuse Occasions — 2112; 294 days
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 3 N=248 Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
Gastrointestinal Stromal Tumors
Primary: Progression-free Survival (PFS) From Central Radiology Review Based on Primary Analysis (Data Cut-off: June, 2008) — 109.0; 111.0 days
Phase 3 N=1,292 Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
Multiple Sclerosis
Primary: Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study — 0.203; 0.161; 0.331 Estimate relapses per year
Phase 3 N=988 The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. — 0.02; -0.51 Percentage point of total HbA1c
Phase 3 N=330 Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies — 1.81; 1.89 ratio — p=0.649
Phase 3 N=1,027 A Comparison of Once a Day Dose Compared to 2 Doses/Day
Ulcerative Colitis
Primary: Percentage of Patients Remaining in Remission at Month 6, ITT Population, Determined by the Simple Clinical Colitis Activity Index (SCCAI) — 90.5; 91.8 Percentage of…
Phase 3 N=168 Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
Vaccines · Pneumococcal Conjugate Vaccine
Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series. — 98.8; 100.0…
Phase 3 N=21 Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis
Leukemia · Fungal Infection
Primary: Percentage of Samples With BG Levels > 60pg/ml — 4; 5; 3; 3 percent of blood samples
Phase 3 N=2,368 Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes
Coronary Disease · Cardiovascular Diseases · Heart Diseases
Primary: Number of Participants With All-Cause Mortality — 80; 75; 80; 81 participants — p=0.97
Phase 3 N=1,132 Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
Diabetes Mellitus, Non-Insulin-Dependent
Primary: Hemoglobin A1c Measurement — 7.37; 7.50; 7.49; 7.33 percent HbA1c
Phase 3 N=467 Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 — 7.91; 7.98; 7.85; 7.88 Percentage of glycosylated hemoglobins — p=<.0001
Phase 3 N=325 XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
Restless Legs Syndrome
Primary: Change From Baseline in IRLS Rating Scale Total Score at Week 12 Using Last Observation Carried Forward (LOCF) — -9.8; -13.0 scores on a scale — p=0.0015
Phase 3 N=577 ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial
Diabetic Nephropathy · Type 2 Diabetes Mellitus · Proteinuria
Primary: Renal Composite Outcomes — 116; 129 participants — p=0.79